Delving into the Latest Updates on ZL-65 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCongenital Disorders+ [4]

Active Indication

Cryopyrin-Associated Periodic SyndromesMultiple SclerosisAutoinflammatory disease+ [2]

Inactive Indication-

Originator Organization

Chengdu Zenitar Biomedical Technology Co., Ltd

Active Organization

Chengdu Zenitar Biomedical Technology Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Starting from the [PtCl(η1-C2H4OMe)(phen)] (phen = 1,10-phenanthroline, 1) platinum(II) precursor, we synthesized and characterized by multinuclear NMR new [Pt(η1-C2H4OMe)(L)(phen)]+ (L = NH3, 2; DMSO, 3) complexes. These organometallic species, potentially able to interact with cell membrane organic cation transporters (OCT), violating some of the classical rules for antitumor activity of cisplatin analogues, were evaluated for their cytotoxicity. Interestingly, despite both complexes 2 and 3 resulting in greater cell uptake than cisplatin in selected tumor cell lines, only 3 showed comparable or higher antitumor activity. General low cytotoxicity of complex 2 in the tested cell lines (SH-SY5Y, SK-OV-3, Hep-G2, Caco-2, HeLa, MCF-7, MG-63, ZL-65) appeared to depend on its stability towards solvolysis in neutral water, as assessed by NMR monitoring. Differently, the [Pt(η1-C2H4OMe)(DMSO)(phen)]+ (3) complex was easily hydrolyzed in neutral water, resulting in a comparable or higher cytotoxicity in cancer cells with respect to cisplatin. Further, both IC50 values and the uptake profiles of the active complex appeared quite different in the used cell lines, suggesting the occurrence of diversified biological effects. Nevertheless, further studies on the metabolism of complex 3 should be performed before planning its possible use in tissue- and tumor-specific drug design.

100 Deals associated with ZL-65

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cryopyrin-Associated Periodic Syndromes	Preclinical	China	Chengdu Zenitar Biomedical Technology Co., Ltd	22 Aug 2024
Multiple Sclerosis	Preclinical	China	Chengdu Zenitar Biomedical Technology Co., Ltd	22 Aug 2024
Autoinflammatory disease	Preclinical	China	Chengdu Zenitar Biomedical Technology Co., Ltd	22 Mar 2024
Gout	Preclinical	China	Chengdu Zenitar Biomedical Technology Co., Ltd	12 Oct 2022
Nonalcoholic Steatohepatitis	Preclinical	China	Chengdu Zenitar Biomedical Technology Co., Ltd	12 Oct 2022